Skip to main content
OpenTrials
Enrolling by invitation

NCT Number: NCT07216508

Liver Transplant CGM

This investigator initiated study aims to describe continuous glucose monitoring (CGM) based glycemic metrics after discharge from liver transplant and assess relationship with glycemic metrics and liver transplant outcomes.

Enrolling by invitation

Interested in participating?

Request Info

Key information

Conditions

Liver Transplant Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Hyperglycemia Metabolic Diseases Nutritional and Metabolic Diseases Post Transplant Diabetes Type 2 Diabetes

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Mount Sinai Hospital

New York, 10029, United States

About this study

Liver transplant participants will be recruited. Participants will wear a blinded sensor after hospital discharge for up to 30 days. Data can be shared with participant and the providers retrospectively. Participants will be invited to wear another blinded sensor at 6 and 12 months.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • inpatient liver transplant participants who have had an inpatient glucose greater than 180mg/dL

Exclusion criteria

  • having a planned discharge to a rehabilitation or nursing facility,
  • a contraindication to sensor placement,
  • if discharge is anticipated to be >30 days post-transplant, or
  • if recent transplant also included a kidney or pancreas transplant

Treatment and study plan

Libre 3+

Device

Blinded CGM will be worn by all participants

Other names: blinded CGM

Primary outcomes

  1. Time in range

    Time frame: 28 days

    Time in range 70-180mg/dL

Secondary outcomes

  1. Percent time >180mg/dL

    Time frame: 28 days

    Percent time >180mg/dL

  2. Percent time >250mg/dL

    Time frame: 28 days

    Percent time >250mg/dL

  3. Percent time <70mg/dL

    Time frame: 28 days

    Percent time <70mg/dL

  4. Percent time <54mg/dL

    Time frame: 28 days

    Percent time <54mg/dL

  5. Transplant outcomes

    Time frame: 1 year

    Rate and time to of wound complications, vascular complications, biliary complications, acute kidney injury, transplant rejection, and readmissions

Sponsors and collaborators

Lead sponsor

Icahn School of Medicine at Mount Sinai

Other

Registry information

Official study title

Post-discharge Glycemic Control After Liver Transplant and Impact on Transplant Outcomes

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Oct 14, 2025
Registry last updated
Aug 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.